Premium
The exploration of novel systemic biomarkers of chronic obstructive pulmonary disease with different levels of the severity
Author(s) -
Ishihara Yoko,
Nakao Motoyuki
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.1262.7
Subject(s) - copd , medicine , asthma , biomarker , systemic inflammation , outpatient clinic , immunology , inflammation , biochemistry , chemistry
The burden of chronic obstructive pulmonary disease (COPD) is glowing worldwide. COPD is characterized by progressive airflow limitation associated with lung and systemic inflammation, and is caused mainly by cigarette smoking and second‐hand smoke. The present study assessed serum cytokine/chemokine profiles in outpatient with COPD, and in the subject free of respiratory diseases. The purpose of this study is to find out useful biomarker of COPD. Method Subjects were recruited at the hospital, clinic and healthcare center in Yamaguchi, Nagasaki and Kumamoto prefecture, Japan. 48 patients with COPD and age‐ and sex‐matched control subjects were involved in this study. Serum samples were analyzed using MAGPIX system magnetic‐bead based multi‐analyte (29 analyte) panels. Result In the subjects, 35 patients with bronchial asthma occurred with COPD was included. The prevalence of comorbidities such as hypertension and diabetes were not significantly different except for allergic rhinitis, which was only found in the patients group. When compared with the control group, IL‐6, IL‐15, TNFβ, and IP‐10 (CXCL10/interferon‐γ‐inducible protein 10) levels were significantly higher in the patient group. IL‐6 and IL‐15 was not detected in the control group, and TNFβ was only found one subject in the control group. Interestingly, EGF levels were significant higher in the control group than in the patients group although EGF level has been reported to be increased in COPD patients. When the subjects were stratified by the severity of COPD, only IP‐10 showed positive association with the severity of COPD. Current or ex‐smoking also increased IP‐10 levels in the patient group although the difference was not significant because of small sample number of never smokers in the patient group. When the subjects were divided by smoking status, IP‐10 levels in current or ex‐smokers were higher than those in never‐smokers but the difference was not significant. Conclusions Results obtained in this study showed that differential expression of biomarkers is present in the patients with COPD, and in the control subjects. Large part of these biomarkers showed higher levels by the presence of COPD or experience of smoking. IP‐10 levels were also influenced by the smoking experience, however, the significance was only found in the patient group. These results suggest that serum IP‐10 is one of the promising candidates for novel biomarker of COPD and its severity. Support or Funding Information This study was supported by Grants‐in‐Aid for Scientific Research (B) 20406001, 23406001 and (C) 26340053, and a “MEXT‐Supported Program for the Strategic Research Foundation at Private Universities” from the Ministry of Education, Culture, Sports, Science and Technology, Japan.